Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Global Ecology Corp. engages in the development, production and marketing of advanced waste remediation technologies that address universal environmental issues, which include organic soil revitalization, reduction of greenhouse gas emissions, solid waste remediation and point-of-use water purification solutions. The company was founded in 1993 and is headquartered in Las Vegas, NV.

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021

Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021

Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.

Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Departure of Chief, Business Operations

Acorda Therapeutics Announces Departure of Chief, Business Operations

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.

Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs.

Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million in cash. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda's patients and continued adheren

Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into “At The Market” Offering Agreement

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Health Care Conference on Thursday, January 14, at 5:20 PM ET. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com. An archived version of the webcast will be available following the presentation. About Acorda Therapeu

Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11th -14th H.C. Wainwright BIOCONNECT Virtual Conference. An audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com. For more information about the conference, please visit the event website at www.hcwevents.com/bioconnect. About Acorda The

Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company's common stock will begin trading on a split-adjusted basis at the market open on January 4, 2021. The reverse stock split was effected in accordance with the authorization adopted by Aco

Acorda Therapeutics Announces Completion of One-for-Six Reverse Stock Split

Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Acorda (ACOR) a New Buy Stock

Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.

Implied Volatility Surging for Acorda (ACOR) Stock Options

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call Transcript

Acorda (ACOR) delivered earnings and revenue surprises of 23.33% and 80.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue Estimates

Shares of Acorda Therapeutics (NASDAQ:ACOR) increased 8.33% after the company reported Q3 results. Quarterly Results Earnings per share rose 50.00% over the past year to ($0.23), which beat the estimate of ($0.31).

Acorda Therapeutics: Q3 Earnings Insights

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the third quarter ended September 30, 2020. “We are encouraged by the 24% increase in INBRIJA net sales over the second quarter, even with the challenges posed by the second wave of COVID-19. We are also pleased that coverage for INBRIJA continued to increase during the quarter, with over 96% of commercially-insured patients now having access to it,” said Ron Cohen, M.D., Acorda's Pr

Acorda Reports Third Quarter 2020 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tuesday, November 3 at 4:30 p.m. ET. To participate in the Webcast/Conference call, please note there is a new pre-registration process. To register for the Webcast/Conference Call, use the link below: http://www.directeventreg.com/registration/event/4177747 **When registering please type your phone number wit

Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acorda Therapeutics (ACOR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Acorda Therapeutics (ACOR) Stock?

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2020 Results - Earnings Call Transcript

Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 0.66% after the company reported Q2 results.

Acorda Therapeutics: Q2 Earnings Insights

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.

Acorda Reports Second Quarter 2020 Financial Results

Acorda Second Quarter 2020 Update: Webcast/Conference Call Scheduled for August 4, 2020

Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?

News for Acorda Therapeutics Stock (ACOR)